Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Profile

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2019

At a glance

  • Drugs Tafasitamab (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors MorphoSys
  • Most Recent Events

    • 25 Jun 2019 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
    • 25 Jun 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
    • 09 Feb 2018 Results assessing the antitumor activity and safety of MOR208 in patients with relapsed or refractory B-cell non-Hodgkins lymphoma, published in the Annals of Oncology Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top